Funding profile · Life science tools

Andson Biotech

Two Form D filings under one CIK, $8,335,000 of equity sold to 66 investor slots, and $1,706,342 of NIH SBIR money. Neither filing names a venture fund.

$8.34MEquity sold across two Form D filings, 2024 and 2025
$1.71MNIH SBIR awards on record, FY2025 and FY2026
66Investor slots across the two filings, 37 then 29
$265KUnsold of the $5.0M offering at the October 2025 filing date

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2020 to 2021 Pre-company grants and program support Not disclosed Biolocity, Georgia Research Alliance Company-stated
Winter 2022 Y Combinator batch Not disclosed Y Combinator YC data
2022 to 2023 Accelerator programs, non-equity or undisclosed Not disclosed Merck Digital Sciences Studio inaugural cohort; BioTools Innovator 2023 finalist Company-stated
Mar 2024 Seed, equity, Rule 506(b) $3,600,000 sold of $3,600,000 37 investors; round led by Glenn H. Epstein per the company release Form D
Oct 2025 Equity, Rule 506(b); stage not stated in the filing $4,735,000 sold of $5,000,000 29 investors; no lead named in the filing Form D
Aug 2025 to Feb 2027 NIH SBIR Phase I, 1R43GM159530-01 $302,671 NIGMS NIH
Sep 2026 to Feb 2028 NIH SBIR Phase II, 1R44GM165164-01 $1,403,671 NIGMS NIH

What the filings show

Andson Biotech Inc. · Form D · filed Oct 22, 2025

First sale
Oct 17, 2025
Offered
$5,000,000 equity
Sold
$4,735,000 · $265,000 remaining
Investors
29 · average about $163,300
Minimum
$0 minimum outside investment
Exemption
Rule 506(b)
Revenue range
Decline to Disclose
Proceeds to officers
$0
Related persons
Mason Chilmonczyk (executive officer, director); Jim Filippini (executive officer); Andrei Fedorov, Thomas O’Brien, James Ross, Glenn Epstein (directors)
Filing
SEC EDGAR, CIK 0002017131

Andson Biotech Inc. · Form D · filed Mar 26, 2024

First sale
Mar 12, 2024
Offered
$3,600,000 equity
Sold
$3,600,000 · $0 remaining
Investors
37 · average about $97,300
Minimum
$5,000 minimum outside investment
Exemption
Rule 506(b)
Revenue range
Decline to Disclose
Proceeds to officers
$250,000
Related persons
Mason Chilmonczyk (executive officer, director); Andrei Fedorov, Thomas O’Brien, James Ross (directors)
Filing
SEC EDGAR, CIK 0002017131

Reading the filings

  1. Fewer investors, bigger checks.In 2024, $3,600,000 came from 37 investors, about $97,300 each. In 2025, $4,735,000 came from 29 investors, about $163,300 each. The count fell by eight while the average check rose about 68 percent. Neither filing reports sales commissions or finders fees, and neither names a fund.
  2. The lead investor took his board seat between the two filings.The April 2024 release says the seed was led by Glenn H. Epstein and that “He will serve on Andson’s board of directors.” He is not among the four related persons on the March 2024 filing. He appears as a director on the October 2025 filing, which also adds Jim Filippini as an executive officer. Four related persons became six.
  3. The 2025 filing followed the press release by one day.First sale Oct 17, 2025. Release dated Oct 21. Form D filed Oct 22, five days after first sale and inside the 15 day window. The 2024 sequence ran the other way: first sale Mar 12, filed Mar 26, announced Apr 30, thirty five days after the filing landed.
  4. The round was announced at a number the filing does not reach.The company release is headed “Andson Biotech Secures $5.0M in Funding” while its own first sentence says the company “today announced the successful close of a $4.7 million round of funding”. Jones Day, which advised on the deal, states $4.7 million. Georgia Tech’s March 2026 profile refers to “a $3.6 million round in 2024 and a $5 million round in 2025”. The filing settles it at $4,735,000 sold against $5,000,000 offered, with $265,000, or 5.3 percent, unsold at the filing date. No amendment has been filed.
  5. A quarter of a million dollars of the seed was routed to insiders.The March 2024 filing reports $250,000 of gross proceeds to be paid to executive officers, directors or promoters. The October 2025 filing reports $0 for the same item. In a $3.6 million round that is 6.9 percent of the raise.
  6. Non-dilutive money is now a fifth of the equity.$1,706,342 of NIH SBIR awards against $8,335,000 of equity sold, or 20.5 percent. Most of it is recent: the $1,403,671 Phase II started Sep 3, 2026, nineteen days before this page’s data date, and runs to Feb 29, 2028.

Commercial signals

Signal Detail Source type
Product DynaChip X1 launched at ASMS 2025 in Baltimore, June 1 to 5, 2025, from booth 212 with seven posters. Company-stated
Field presence 2026 ASMS 2026 in San Diego, booth 715, one oral talk and seven posters. IMSC 2026 in Lyon, booth 38. BMSS 2026 in Leeds. CASSS MS 2026 in Rockville. Company-stated
Revenue Decline to Disclose on both Form D filings. No revenue figure appears in any source found. Public record
Customers None named. Target segments given to Hypepotamus in October 2025: large biopharma and biotechs, contract development and manufacturing organizations, and academic investigators. Not found
Headcount Three to ten over the year to August 2025 per Georgia Life Sciences; eleven in October 2025, eight of them in Atlanta; about a dozen in March 2026. Independent
Regulatory No FDA 510(k), no PMA, no registered trial, and none expected for bench equipment. Public record
Counsel Jones Day advised on the October 2025 raise and states the amount as $4.7 million. Counsel

What to watch

  • A Form D for any round after October 2025, due within 15 days of first sale.
  • An amendment to the 2025 filing, which would show whether the remaining $265,000 was sold.
  • Whether the revenue range moves off Decline to Disclose on the next filing.
  • A priced institutional round, which would be the first time a fund appears among the related persons.
  • Phase II SBIR output before the award ends on February 29, 2028.

The Andson Biotech story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Cytera CellWorks, now Mytos: Shared investor: Precursor. A London company that builds machines to grow human cells without a human touching them
  • Lygos: Shared investor: Precursor. A Berkeley Lab spinout that taught yeast to make malonic acid without cyanide, then became a specialty chemicals supplier whose polymers end up in shampoo, diapers and
  • Dorian Therapeutics: Shared investor: Precursor. A Stanford spinout that built small molecule blockers of USP16, the enzyme that strips a silencing mark off histone H2A, and pointed them at the arthritic knee
  • Lamar Health: Shared investor: Precursor. A San Francisco startup that builds AI software to automate the referral, benefits verification and prior authorization paperwork behind expensive specialty drugs

Sources

  1. Public recordForm D, Andson Biotech Inc., accession 0002017131-24-000001SEC · Mar 26, 2024
  2. Public recordForm D, Andson Biotech Inc., accession 0002017131-25-000004SEC · Oct 22, 2025
  3. Public recordNIH RePORTER 1R43GM159530-01NIGMS · FY2025
  4. Public recordNIH RePORTER 1R44GM165164-01NIGMS · FY2026
  5. IndependentAndson Biotech raises $4.7 million in capitalJones Day experience page · Oct 2025
  6. IndependentY Combinator-backed Andson Biotech in Atlanta raises $5 MillionHypepotamus, Maija Ehlinger · Oct 30, 2025
  7. IndependentEngineering a Faster Path to Life-Saving TherapiesGeorgia Tech Woodruff School · Mar 18, 2026
  8. IndependentGeorgia Life Sciences Names 2025 Golden Helix Award WinnersGeorgia Life Sciences · Aug 2025
  9. CompanyAndson Biotech Raises $3.6M Seed RoundAndson Biotech · Apr 30, 2024
  10. CompanyAndson Biotech Secures $5.0M in Funding to Accelerate Commercialization, Expand Product PortfolioAndson Biotech · Oct 21, 2025

Compiled from SEC and NIH public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Investor counts are per filing and the same person may appear in both. Healthcare Venture Capital Fund holds no position in Andson Biotech. This page is not an offer to sell or a recommendation to buy any security.